News tagged with insulin glargine
Long-acting insulin analogues in type 1 diabetes: No proof of additional benefit
It has so far not been proven that the long-acting insulin analogues (LAIAs) insulin detemir (trade name: Levemir) and insulin glargine (trade name: Lantus), which are approved for the treatment of type 1 diabetes, offer ...
Medicine & Health / Medical research
May 12, 2010 |
4 / 5 (1) |
0
UNC scientists coordinate study of link between insulin use and cancer in people with diabetes
Type 2 diabetes and obesity are linked to an increased risk of certain cancers. Recently published studies suggested that insulin glargine (a synthetic insulin preparation marketed under the trade name Lantus), ...
Medicine & Health / Diseases, Conditions, Syndromes
Dec 14, 2009 |
not rated yet |
0
Research team responds to concerns about international insulin drug trial
Accumulating safety data from the large, international ORIGIN trial have been reviewed by its independent data monitoring committee, who have concluded that there is no cause for concern.
Medicine & Health / Medical research
Aug 11, 2009 |
not rated yet |
1
Search results for insulin glargine
Ultra-long acting insulin effective with three injections weekly
A U of T study assessing a new longer-acting form of insulin—degludec— has shown that when given once daily it is as effective at controlling blood sugar as existing insulin glargine injections but with lower rates ...
Medicine & Health / Medical research
Mar 11, 2011 |
not rated yet |
1
Experts call for further research into the relationship between insulin therapy and cancer
The benefits of using insulin to treat diabetes far outweigh the risks, but a review just published online by IJCP, the International Journal of Clinical Practice, suggests that commonly used diabetes therapies may differ ...
Medicine & Health / Diseases, Conditions, Syndromes
Mar 02, 2010 |
not rated yet |
0
FDA reviewing safety of Sanofi's Lantus insulin
(AP) -- The Food and Drug Administration said Wednesday it is reviewing data on the safety of Lantus, a synthetic insulin made by Sanofi-Aventis SA.
Medicine & Health / Medications
Jul 01, 2009 |
1 / 5 (1) |
0
Insulin analogue glargine possibly increases cancer risk
The risk of cancer possibly increases if patients with diabetes use the long-acting insulin analogue glargine instead of human insulin. The Institute for Quality and Efficiency in Health Care (IQWiG), in collaboration with ...
Jun 26, 2009 |
not rated yet |
0
Long-acting insulin analogues in type 2 diabetes: advantage over human insulin not proven
It has so far not been proven that long-acting insulin analogues (LAIAs) have an advantage over conventional human insulin in the treatment of patients with type 2 diabetes. Even though the results of a 5-year study are available ...
Medicine & Health / Medical research
Apr 03, 2009 |
not rated yet |
0
Landmark trial to evaluate cardioprotective properties of insulin
The ability of insulin to limit heart-tissue damage during a heart attack will be tested in a landmark clinical trial led by Paresh Dandona, M.D., Ph.D., University at Buffalo Distinguished Professor in the departments of ...
Medicine & Health / Medical research
Nov 09, 2007 |
not rated yet |
0
List of search results for insulin glargine
